Stoke Therapeutics (STOK) Net Cash Flow (2018 - 2026)

Stoke Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $74.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 49.3% year-over-year to $74.4 million in Q1 2026; TTM through Mar 2026 was -$116.2 million, a 220.5% decrease from a year earlier, with the FY2025 full-year figure at -$43.8 million, up 30.67% from the prior year.
• Net Cash Flow grew to $74.4 million in Q1 2026 per STOK's latest filing, from $826000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $146.8 million in Q1 2025 and bottomed at -$173.3 million in Q2 2025.
• The 5-year median for Net Cash Flow is $160000.0 (2022), against an average of $818588.2.
• Across the five-year window, Net Cash Flow plunged 1986.41% in 2024 and jumped 1241.69% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $160000.0 in 2022, then soared by 815.62% to $1.5 million in 2023, then tumbled by 1588.46% to -$21.8 million in 2024, then surged by 103.79% to $826000.0 in 2025, then jumped by 8911.99% to $74.4 million in 2026.
• Per Business Quant, the three latest STOK Net Cash Flow figures stand at $74.4 million (Q1 2026), $826000.0 (Q4 2025), and -$18.2 million (Q3 2025).